These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 29192414)

  • 21. Neoadjuvant Chemotherapy Increases R0 Cytoreduction Rate But Does Not Improve Final Outcome in Advanced Epithelial Ovarian Cancer.
    Medina-Franco H; Cortés-González R; Lambreton-Hinojosa F; Fimbres-Morales A; Vargas-Siordia JC
    Ann Surg Oncol; 2017 May; 24(5):1330-1335. PubMed ID: 27995454
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical significance of systematic retroperitoneal lymphadenectomy during interval debulking surgery in advanced ovarian cancer patients.
    Iwase H; Takada T; Iitsuka C; Nomura H; Abe A; Taniguchi T; Takizawa K
    J Gynecol Oncol; 2015 Oct; 26(4):303-10. PubMed ID: 26197771
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The efficacy of systematic lymph node dissection in advanced epithelial ovarian cancer during interval debulking surgery performed after neoadjuvant chemotherapy.
    Eoh KJ; Yoon JW; Lee I; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
    J Surg Oncol; 2017 Sep; 116(3):329-336. PubMed ID: 28542980
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk factors for lymph node metastasis in apparent early-stage epithelial ovarian cancer: implications for surgical staging.
    Powless CA; Aletti GD; Bakkum-Gamez JN; Cliby WA
    Gynecol Oncol; 2011 Sep; 122(3):536-40. PubMed ID: 21636114
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Minimal access surgery compared to laparotomy for secondary surgical cytoreduction in patients with recurrent ovarian carcinoma: Perioperative and oncologic outcomes.
    Eriksson AGZ; Graul A; Yu MC; Halko A; Chi DS; Zivanovic O; Gardner GJ; Sonoda Y; Barakat RR; Abu-Rustum NR; Leitao MM
    Gynecol Oncol; 2017 Aug; 146(2):263-267. PubMed ID: 28527673
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anesthetic selection and disease-free survival following optimal primary cytoreductive surgery for stage III epithelial ovarian cancer.
    Elias KM; Kang S; Liu X; Horowitz NS; Berkowitz RS; Frendl G
    Ann Surg Oncol; 2015 Apr; 22(4):1341-8. PubMed ID: 25287437
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preoperative predictors that impact the survival and outcome of patients undergoing secondary cytoreduction for ovarian cancer.
    Katsnelson M; Hwang WT; Tahirovic E; Rubin SC; Tanyi JL
    J Obstet Gynaecol; 2018 Apr; 38(3):395-401. PubMed ID: 29385863
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Surgical implications of mesenteric lymph node metastasis from advanced ovarian cancer after bowel resection.
    Baiocchi G; Cestari LA; Macedo MP; Oliveira RA; Fukazawa EM; Faloppa CC; Kumagai LY; Badiglian-Filho L; Menezes AN; Cunha IW; Soares FA
    J Surg Oncol; 2011 Sep; 104(3):250-4. PubMed ID: 21472733
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Success rate and safety of tumor debulking with diaphragmatic surgery for advanced epithelial ovarian cancer and peritoneal cancer.
    Saitou M; Iida Y; Komazaki H; Narui C; Matsuno K; Kawabata A; Ueda K; Tanabe H; Takakura S; Isonishi S; Sasaki H; Okamoto A
    Arch Gynecol Obstet; 2015 Mar; 291(3):641-6. PubMed ID: 25182215
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
    Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA
    Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neoadjuvant Chemotherapy in Advanced Ovarian Cancer: A Single-Institution Experience and a Review of the Literature.
    Loizzi V; Leone L; Camporeale A; Resta L; Selvaggi L; Cicinelli E; Cormio G
    Oncology; 2016; 91(4):211-216. PubMed ID: 27487241
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of the Time-Varying Effect of Prognostic Factors on Survival in Ovarian Cancer.
    Chang C; Chiang AJ; Wang HC; Chen WA; Chen J
    Ann Surg Oncol; 2015 Nov; 22(12):3976-80. PubMed ID: 25777089
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Extended left upper quadrant resection during primary cytoreductive surgery for Stage IV ovarian cancer.
    Sawyer BT; LaFargue CJ; Bristow RE
    Gynecol Oncol; 2016 Aug; 142(2):378. PubMed ID: 27264212
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preoperative factors predicting survival after secondary cytoreduction for recurrent ovarian cancer.
    Frederick PJ; Ramirez PT; McQuinn L; Milam MR; Weber DM; Coleman RL; Gershenson DM; Landen CN
    Int J Gynecol Cancer; 2011 Jul; 21(5):831-6. PubMed ID: 21613957
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Distal pancreatectomy with splenectomy for the management of splenic hilum metastasis in cytoreductive surgery of epithelial ovarian cancer.
    Xiang L; Tu Y; He T; Shen X; Li Z; Wu X; Yang H
    J Gynecol Oncol; 2016 Nov; 27(6):e62. PubMed ID: 27550408
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience.
    Ghisoni E; Katsaros D; Maggiorotto F; Aglietta M; Vaira M; De Simone M; Mittica G; Giannone G; Robella M; Genta S; Lucchino F; Marocco F; Borella F; Valabrega G; Ponzone R
    J Ovarian Res; 2018 May; 11(1):42. PubMed ID: 29843747
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radical surgical procedure improves survival time in patients with recurrent ovarian cancer.
    Jänicke F; Hölscher M; Kuhn W; von Hugo R; Pache L; Siewert JR; Graeff H
    Cancer; 1992 Oct; 70(8):2129-36. PubMed ID: 1394042
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efforts at maximal cytoreduction improve survival in ovarian cancer patients, even when complete gross resection is not feasible.
    Wallace S; Kumar A; Mc Gree M; Weaver A; Mariani A; Langstraat C; Dowdy S; Bakkum-Gamez J; Cliby W
    Gynecol Oncol; 2017 Apr; 145(1):21-26. PubMed ID: 28159407
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic factors for maximally or optimally cytoreduced stage III nonserous epithelial ovarian carcinoma treated with carboplatin/paclitaxel chemotherapy.
    Cuylan ZF; Meydanli MM; Sari ME; Akbayir O; Celik H; Dede M; Sahin H; Gungorduk K; Kuscu E; Ozgul N; Gungor T; Ayhan A
    J Obstet Gynaecol Res; 2018 Jul; 44(7):1284-1293. PubMed ID: 29727055
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma.
    Chi DS; McCaughty K; Diaz JP; Huh J; Schwabenbauer S; Hummer AJ; Venkatraman ES; Aghajanian C; Sonoda Y; Abu-Rustum NR; Barakat RR
    Cancer; 2006 May; 106(9):1933-9. PubMed ID: 16572412
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.